What is the Market's View on G1 Therapeutics Inc (GTHX) Stock's Price and Volume Trends Thursday?

G1 Therapeutics Inc (GTHX) stock is lower by 9.54% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

G1 Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on GTHX!

See Full GTHX Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With GTHX Stock Today?

G1 Therapeutics Inc (GTHX) stock is up 5.33% while the S&P 500 is down -1.2% as of 10:05 AM on Thursday, May 12. GTHX has risen $0.24 from the previous closing price of $4.50 on volume of 98,635 shares. Over the past year the S&P 500 is lower by -6.36% while GTHX is down -77.19%. GTHX lost -$4.03 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for G1 Therapeutics Inc click here.

More About G1 Therapeutics Inc

G1 Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat most types of cancer such as cell lung cancer and breast cancer and designs them to combine - and enhance - the anti-tumor activity of current therapies. Click Here to get the full Stock Report for G1 Therapeutics Inc stock.